How does 0QFP's PE Ratio compare to its peers?

0QFP is good value based on its Price-To-Earnings Ratio (9.1x) compared to the peer average (26.4x).

How does 0QFP's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0QFP is good value based on its Price-To-Earnings Ratio (9.1x) compared to the European Pharmaceuticals industry average (20.1x).

What is 0QFP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0QFP's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 0QFP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0QFP (HUF5040) is trading below our estimate of [[fair value]] (HUF10890)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

0QFP Stock Overview

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. More details

0QFP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	5/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 53.7% below our estimate of its fair value

Earnings are forecast to grow 13.04% per year

Earnings grew by 121.5% over the past year

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.6b

GSK

LSE:GSK

UK£55.1b

Animalcare Group

AIM:ANCR

UK£148.5m

AstraZeneca

LSE:AZN

UK£170.4b

Price History & Performance

Summary of share price highs, lows and changes for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Historical stock prices
Current Share Price	Ft5,040.00
52 Week High	Ft11,104.66
52 Week Low	Ft8,857.97
Beta	0.34
1 Month Change	-53.09%
3 Month Change	n/a
1 Year Change	-45.29%
3 Year Change	-43.43%
5 Year Change	-21.98%
Change since IPO	34.76%

Recent updates

Shareholder Returns

	0QFP	GB Pharmaceuticals	GB Market
7D	-52.2%	2.3%	0.3%
1Y	-45.3%	-2.3%	6.6%

Return vs Industry: 0QFP underperformed the UK Pharmaceuticals industry which returned -2.3% over the past year.

Return vs Market: 0QFP underperformed the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0QFP's price volatile compared to industry and market?
0QFP volatility
0QFP Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.7%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0QFP's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0QFP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1901	11,603	Gabor Orban	www.gedeonrichter.com/hu-hu

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. It operates through two segments, Pharmaceuticals, and Wholesale and Retail.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary

How do Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's earnings and revenue compare to its market cap?
0QFP fundamental statistics
Market cap	Ft1.92t
Earnings (TTM)	Ft211.64b
Revenue (TTM)	Ft839.60b

9.1x

P/E Ratio

2.3x

P/S Ratio

Is 0QFP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QFP income statement (TTM)
Revenue	Ft839.60b
Cost of Revenue	Ft269.96b
Gross Profit	Ft569.64b
Other Expenses	Ft358.00b
Earnings	Ft211.64b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 28, 2025

Earnings per share (EPS)	1.16k
Gross Margin	67.85%
Net Profit Margin	25.21%
Debt/Equity Ratio	5.4%

How did 0QFP perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

35%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 19:41
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Simon Mather	Barclays
Samuel England	Berenberg
Victoria Lambert	Berenberg

0QFP Stock Overview

Rewards

Risk Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors

LSE:HIK

UK£4.6b

LSE:GSK

UK£55.1b

AIM:ANCR

UK£148.5m

LSE:AZN

UK£170.4b

Price History & Performance

Recent News & Updates

Now 54% undervalued

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025

Now 62% undervalued after recent price drop

Third quarter 2024 earnings released: EPS: Ft203 (vs Ft294 in 3Q 2023)

Second quarter 2024 earnings released: EPS: Ft383 (vs Ft155 in 2Q 2023)

Recent updates

Now 54% undervalued

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025

Now 62% undervalued after recent price drop

Third quarter 2024 earnings released: EPS: Ft203 (vs Ft294 in 3Q 2023)

Second quarter 2024 earnings released: EPS: Ft383 (vs Ft155 in 2Q 2023)

Investor sentiment deteriorates as stock falls 45%

Upcoming dividend of Ft423 per share

High number of new directors

First quarter 2024 earnings released: EPS: Ft373 (vs Ft210 in 1Q 2023)

Dividend of Ft423 announced

High number of new directors

Full year 2023 earnings released: EPS: Ft860 (vs Ft907 in FY 2022)

Full year 2023 earnings released: EPS: Ft860 (vs Ft835 in FY 2022)

Investor sentiment deteriorates as stock falls 43%

Investor sentiment deteriorates as stock falls 43%

Investor sentiment deteriorates as stock falls 42%

Third quarter 2023 earnings released: EPS: Ft294 (vs Ft442 in 3Q 2022)

Now 42% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 41%

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Now 43% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 42%

Now 44% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 45%

Now 45% undervalued after recent price drop

Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis

Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis

Investor sentiment deteriorates as stock falls 43%

Now 49% undervalued after recent price drop

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: Ft155 (vs Ft411 in 2Q 2022)

Now 42% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 42%

Now 43% undervalued

Investor sentiment deteriorates as stock falls 40%

Now 43% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 40%

Now 43% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 40%

Upcoming dividend of Ft390 per share at 4.5% yield

Now 44% undervalued

Investor sentiment deteriorates as stock falls 40%

First quarter 2023 earnings released: EPS: Ft210 (vs Ft199 in 1Q 2022)

Now 44% undervalued

Investor sentiment deteriorates as stock falls 37%

Now 47% undervalued

Investor sentiment deteriorates as stock falls 35%

Full year 2022 earnings released

Investor sentiment deteriorates as stock falls 33%

Now 32% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 35%

Now 33% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 38%

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.

Now 31% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 33% undervalued after recent price drop